DDrare: Database of Drug Development for Rare Diseases

218. アルポート症候群
［臨床試験数：16，薬物数：24（DrugBank：11），標的遺伝子数：5，標的パスウェイ数：27］

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACE I, ATA II and Statins; ACE-inhibitor; AT1-inhibitor; Atrasentan; BARDOXOLONE METHYL; Bardoxolone; Bardoxolone Methyl; Bardoxolone methyl; Benazepril; Benazepril, Valsartan and Fluvastatin; Delix; Fluvastatin; Gold; HMG-Coenzyme inhibitor (statin); Hydroxychloroquine; Lademirsen (SAR339375); Paricalcitol; RAMIPRIL; RG-012; RG012; RTA 402; Ramipril; Spironolactone; Valsartan

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000036799	2020-10-01	2020-08-25	Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome	Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome	Alport Syndrome	experimental group:Hydroxychloroquine + Benazepril Hydrochloridec;control group:placebo + benazepril hydrochloride;	Shanghai Children's Hospital	NULL	Pending	0	18	Both	experimental group:25;control group:25;	N/A	China
2	NCT00309257 (ClinicalTrials.gov)	January 2004	30/3/2006	Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome	Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome	Alport Syndrome	Drug: ACE I, ATA II and Statins;Drug: Benazepril , Valsartan and Fluvastatin	Mario Negri Institute for Pharmacological Research	NULL	Completed	15 Years	70 Years	Both	9	Phase 2	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000036799

2020-10-01

2020-08-25

Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome

Alport Syndrome

experimental group:Hydroxychloroquine + Benazepril Hydrochloridec;control group:placebo + benazepril hydrochloride;

Shanghai Children's Hospital

NULL

Pending

Both

experimental group:25;control group:25;

N/A

China

NCT00309257
(ClinicalTrials.gov)

January 2004

30/3/2006

Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome

Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome

Alport Syndrome

Drug: ACE I, ATA II and Statins;Drug: Benazepril , Valsartan and Fluvastatin

Mario Negri Institute for Pharmacological Research

NULL

Completed

15 Years

70 Years

Both

Phase 2

Italy